UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) — La Jolla, California

UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) is a clinical research site located in La Jolla, California, United States 92037.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Arteriosclerosis, Hypercholesterolaemia.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130)?

UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) conducted?

UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) has 1 clinical trials on record, with 1 currently active. Their work covers Arteriosclerosis, Hypercholesterolaemia.

Is UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) accredited by Crixeo Health?

UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.